nach oben

Erschienen in:

23.03.2020 | Pulmonale Hypertonie | Leitthema

Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose

verfasst von: Prof. Dr. S. Gläser, R. Glöckl, F. Bonella

Erschienen in: Zeitschrift für Pneumologie | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Komplikationen der idiopathischen pulmonalen Fibrose (IPF) sind für einen relevanten Mortalitätsanteil verantwortlich. Als wichtigstes Beispiel ist diesbezüglich die akute Exazerbation anzuführen, deren Krankenhausletalität über 50 % beträgt bei einem mittleren Überleben von nur wenigen Monaten. Somit kommt der Betrachtung von Komplikationen eine große Bedeutung für Krankheitsverständnis sowie Therapieplanung zu. Des Weiteren ist in den letzten Jahren die Evidenz für pneumologische Rehabilitation bei IPF deutlich gestiegen und wird von der Amerikanischen und Europäischen Gesellschaft für Pneumologie (American Thoracic Society [ATS]/European Respiratory Society [ERS]) zur Verbesserung der körperlichen Leistungsfähigkeit, Lebensqualität und der Symptome empfohlen.

Ryerson CJ, Cottin V, Brown KK, Collard HR (2015) Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 46:512–520PubMed

Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr., Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network I (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636–643PubMedPubMedCentral

Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA (2017) Acute exacerbation and decline in forced Vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc 14:1395–1402PubMed

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, Investigators IT (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082PubMed

Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, investigators IP. (2013) Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 14:73PubMedPubMedCentral

Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ (2016) Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 194:265–275PubMed

Spagnolo P, Molyneaux PL, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F, Tine M, Saetta M, Maher TM, Balestro E (2019) The role of the lung’s microbiome in the pathogenesis and progression of idiopathic pulmonary fibrosis. Int J Mol Sci 20:5618PubMedCentral

Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, Lancaster LH, Wolters PJ, DeRisi J, Ganem D, Collard HR (2011) Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:1698–1702PubMedPubMedCentral

Saraya T, Kimura H, Kurai D, Tamura M, Ogawa Y, Mikura S, Sada M, Oda M, Watanabe T, Ohkuma K, Inoue M, Honda K, Watanabe M, Yokoyama T, Fujiwara M, Ishii H, Takizawa H (2018) Clinical significance of respiratory virus detection in patients with acute exacerbation of interstitial lung diseases. Respir Med 136:88–92PubMedPubMedCentral

10.

Mise K, Capkun V, Jurcev-Savicevic A, Sundov Z, Bradaric A, Mladinov S (2010) The influence of gastroesophageal reflux in the lung: a case-control study. Respirology 15:837–842PubMed

11.

Bandeira CD, Rubin AS, Cardoso PF, Moreira Jda S, Machado Mda M (2009) Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J bras pneumol 35:1182–1189PubMed

12.

Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ (2016) Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE 11:e151425PubMedPubMedCentral

13.

Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–363PubMed

14.

Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T (2015) Risk factors for acute exacerbation of idiopathic pulmonary fibrosis—Extended analysis of pirfenidone trial in Japan. Respir Investig 53:271–278PubMed

15.

Kakugawa T, Sakamoto N, Sato S, Yura H, Harada T, Nakashima S, Hara A, Oda K, Ishimoto H, Yatera K, Ishimatsu Y, Obase Y, Kohno S, Mukae H (2016) Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respir Res 17:79PubMedPubMedCentral

16.

Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, Takemura H (2012) The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg 41:e161–e165PubMed

17.

Ghatol A, Ruhl AP, Danoff SK (2012) Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Am J Physiol 190:373–380

18.

Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U (2014) Baseline KL‑6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med 108:1031–1039PubMed

19.

Ohshimo S, Yamaoka C, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Hirohashi N, Tanigawa K, Bonella F, Guzman J, Costabel U, Kohno N (2015) Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. https://doi.org/10.1183/13993003.congress-2015.OA3510 CrossRef

20.

Konishi K, Gibson KF, Lindell KO, Richards TJ, Zhang Y, Dhir R, Bisceglia M, Gilbert S, Yousem SA, Song JW, Kim DS, Kaminski N (2009) Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 180:167–175PubMedPubMedCentral

21.

Okamoto T, Ichiyasu H, Ichikado K, Muranaka H, Sato K, Okamoto S, Iyonaga K, Suga M, Kohrogi H (2006) Clinical analysis of the acute exacerbation in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi 44:359–367PubMed

22.

Kondoh Y, Cottin V, Brown KK (2017) Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev 26:170050PubMed

23.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr., Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824PubMedPubMedCentral

24.

Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T, Akira M, Kitaichi M, Hayashi S, Inoue Y (2017) High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology 22:1363–1370PubMed

25.

Kim DS, Collard HR, King TE Jr. (2006) Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3:285–292PubMedPubMedCentral

26.

Kawamura K, Ichikado K, Yasuda Y, Anan K, Suga M (2017) Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study. BMC Pulm Med 17:94PubMedPubMedCentral

27.

Ding J, Chen Z, Feng K (2013) Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int J Med Sci 10:903–907PubMedPubMedCentral

28.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A (2016) Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193:178–185PubMed

29.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. (2016) Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 47:243–253PubMedPubMedCentral

30.

Furuya K, Sakamoto S, Shimizu H, Sekiya M, Kinoshita A, Isshiki T, Sugino K, Matsumoto K, Homma S (2017) Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respir Med 126:93–99PubMed

31.

Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM (2017) Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. https://doi.org/10.1183/13993003.01339-2016 CrossRefPubMedPubMedCentral

32.

Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, Investigators IP. (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1:369–376PubMedPubMedCentral

33.

Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M et al (2016) Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution — Authors’ reply. Lancet Respir Med 4(9):e48. https://doi.org/10.1016/S2213-2600(16)30235-1 CrossRefPubMed

34.

Kreuter M, Lederer DJ, Cottin V, Kahn N, Ley B, Vancheri C et al (2019) Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. Eur Respir J 54(6):1901188. https://doi.org/10.1183/13993003.01188-2019 CrossRefPubMedPubMedCentral

35.

Rush B, Wiskar K, Berger L, Griesdale D (2016) The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis. Respir Med 111:72–76PubMed

36.

Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S (2015) Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration 89:201–207PubMed

37.

Isshiki T, Sakamoto S, Homma S (2019) Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Medicina 55(5):E172. https://doi.org/10.3390/medicina55050172 CrossRefPubMed

38.

Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C (2007) Effectiveness of polymyxin B‑immobilized fiber column in sepsis: a systematic review. Crit Care 11:R47PubMedPubMedCentral

39.

Enomoto N, Mikamo M, Oyama Y, Kono M, Hashimoto D, Fujisawa T, Inui N, Nakamura Y, Yasuda H, Kato A, Mimuro S, Doi M, Sato S, Suda T (2015) Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B‑immobilized fiber column improves survival. BMC Pulm Med 15:15PubMedPubMedCentral

40.

Oishi K, Aoe K, Mimura Y, Murata Y, Sakamoto K, Koutoku W, Matsumoto T, Ueoka H, Yano M (2016) Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a polymyxin B‑immobilized fiber column: a retrospective analysis. Intern Med 55:3551–3559PubMedPubMedCentral

41.

Itai J, Ohshimo S, Kida Y, Ota K, Iwasaki Y, Hirohashi N, Bonella F, Guzman J, Costabel U, Kohno N, Tanigawa K (2015) A pilot study: a combined therapy using polymyxin‑B hemoperfusion and extracorporeal membrane oxygenation for acute exacerbation of interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 31:343–349PubMed

42.

Trudzinski FC, Kaestner F, Schafers HJ, Fahndrich S, Seiler F, Bohmer P, Linn O, Kaiser R, Haake H, Langer F, Bals R, Wilkens H, Lepper PM (2016) Outcome of Patients with Interstitial Lung Disease Treated with Extracorporeal Membrane Oxygenation for Acute Respiratory Failure. Am J Respir Crit Care Med 193:527–533PubMed

43.

Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, Xue J, Zhang Y, Duncan SR (2015) Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS ONE 10:e127771PubMedPubMedCentral

44.

Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, Bon J, Soejima M, Levesque MC, Lindell KO, Gibson KF, Kaminski N, Banga G, Oddis CV, Pilewski JM, Sciurba FC, Donahoe M, Zhang Y, Duncan SR (2013) Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 187:768–775PubMedPubMedCentral

45.

Hirai K, Homma T, Yamaguchi F, Yamaguchi M, Suzuki S, Tanaka A, Ohnishi T, Sagara H (2019) Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report. BMC Pulm Med 19:15PubMedPubMedCentral

46.

Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J, Task F. (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25:2243–2278PubMed

47.

Olschewski H, Hoeper MM, Borst MM, Ewert R, Grunig E, Kleber FX, Kopp B, Opitz C, Reichenberger F, Schmeisser A, Schranz D, Schulze-Neick I, Wilkens H, Winkler J, Worth H (2006) Diagnosis and therapy of chronic pulmonary hypertension. Pneumologie 60:749–771PubMed

48.

Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H et al (2019) Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 53(1):1801914. https://doi.org/10.1183/13993003.01914-2018 CrossRefPubMedPubMedCentral

49.

Raghu G, Amatto VC, Behr J, Stowasser S (2015) Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 46:1113–1130PubMed

50.

Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD (2007) Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30:715–721PubMed

51.

Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH (2005) Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128:2393–2399PubMed

52.

Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF (2010) Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 35:105–111PubMed

53.

Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129:746–752PubMed

54.

Magnussen H, Hauck RW, Worth H, Herth FJ (2014) Statement to long term oxygen therapy. Pneumologie 68:591–593PubMed

55.

Nishimoto K, Fujisawa T, Yoshimura K, Enomoto Y, Enomoto N, Nakamura Y, Inui N, Sumikawa H, Johkoh T, Colby TV, Suda T (2018) The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. Respirology 23:519–525PubMed

56.

Sahn SA, Heffner JE (2000) Spontaneous pneumothorax. N Engl J Med 342:868–874PubMed

57.

Noppen M, De Keukeleire T (2008) Pneumothorax. Respiration 76:121–127PubMed

58.

Mendes P, Wickerson L, Helm D, Janaudis-Ferreira T, Brooks D, Singer LG, Mathur S (2015) Skeletal muscle atrophy in advanced interstitial lung disease. Respirology 20:953–959PubMed

59.

Leuchte HH, Mernitz P, Baezner C, Baumgartner RA, von Wulffen W, Neurohr C, Behr J (2015) Self-report daily life activity as a prognostic marker of idiopathic pulmonary fibrosis. Respiration 90:460–467PubMed

60.

McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y (2015) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003793.pub3 CrossRefPubMed

61.

Behr J, Gunther A, Ammenwerth W, Bittmann I, Bonnet R, Buhl R, Eickelberg O, Ewert R, Glaser S, Gottlieb J, Grohe C, Kreuter M, Kroegel C, Markart P, Neurohr C, Pfeifer M, Prasse A, Schonfeld N, Schreiber J, Sitter H, Theegarten D, Theile A, Wilke A, Wirtz H, Witt C, Worth H, Zabel P, Muller-Quernheim J, Costabel U (2013) German guideline for diagnosis and management of idiopathic pulmonary fibrosis. Pneumologie 67:81–111PubMed

62.

Singh SJ, Puhan MA, Andrianopoulos V, Hernandes NA, Mitchell KE, Hill CJ, Lee AL, Camillo CA, Troosters T, Spruit MA, Carlin BW, Wanger J, Pepin V, Saey D, Pitta F, Kaminsky DA, McCormack MC, MacIntyre N, Culver BH, Sciurba FC, Revill SM, Delafosse V, Holland AE (2014) An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J 44:1447–1478PubMed

63.

Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schonheit-Kenn U, Neurohr C, Behr J, Kenn K (2013) Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 42:444–453PubMed

64.

Kenn K, Gloeckl R, Behr J (2013) Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis—a review. Respiration 86:89–99PubMed

65.

Gloeckl R, Halle M, Kenn K (2012) Interval versus continuous training in lung transplant candidates: a randomized trial. J Heart Lung Transplant 31:934–941PubMed

66.

Wickerson L, Brooks D, Granton J, Reid WD, Rozenberg D, Singer LG et al (2019) Interval aerobic exercise in individuals with advanced interstitial lung disease: a feasibility study. Physiother Theory Pract 18:1–9. https://doi.org/10.1080/09593985.2019.1678207 CrossRef

67.

Dowman L, Hill CJ, Holland AE (2014) Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006322.pub3 CrossRefPubMed

68.

Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, Glaspole I, Goh NSL, Southcott AM, Burge AT, Gillies R, Martin A, Holland AE (2017) The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax 72:610–619PubMed

69.

Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, Khalil N, Collard HR, Garvey C (2014) Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med 108:203–210PubMed

70.

Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, Troosters T (2018) Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res 19:182PubMedPubMedCentral

71.

Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 93:391–398

72.

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686.

73.

Lim RK, Humphreys C, Morisset J, Holland AE, Johannson KA, the O2 Delphi Collaborators (2019) Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. Eur Respir J 54(2):1900421. https://doi.org/10.1183/13993003.00421-2019 CrossRefPubMed

74.

Markart P, Günther A (2017) Akute Exazerbation der IPF—revidierte Definition und Diagnosekriterien. Pneumonews 9(1):16–17

Titel: Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
verfasst von: Prof. Dr. S. Gläser
R. Glöckl
F. Bonella
Publikationsdatum: 23.03.2020
Verlag: Springer Medizin
Schlagwörter: Pulmonale Hypertonie
Idiopathische Lungenfibrose
Pulmonale Hypertonie
Pertussis
Pulmonale Hypertonie
Pulmonale Hypertonie
Pneumologie
Erschienen in: Zeitschrift für Pneumologie / Ausgabe 3/2020
Print ISSN: 2731-7404
Elektronische ISSN: 2731-7412
DOI: https://doi.org/10.1007/s10405-020-00313-w

Idiopathische Lungenfibrose

Idiopathische Lungenfibrose
Editorial

Belastungsdyspnoe, Aszites und unklare Hepatopathie – Ihre Diagnose?

AV-Fisteln
Kasuistik

Mitteilungen des Berufsverbands der Pneumologen in Baden-Württemberg

Mitteilungen des Berufsverbands der Pneumologen in Baden-Württemberg

Pathogenese der idiopathischen Lungenfibrose aus dem Blickwinkel der Genetik

Idiopathische Lungenfibrose
Leitthema

Bedeutung von Komorbiditäten bei der idiopathische Lungenfibrose

Koronare Herzerkrankung
Leitthema

Antifibrotische Therapie der idiopathischen pulmonalen Fibrose

Diarrhoe
Leitthema

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schützt das tägliche Glas Milch vor Darmkrebs?

17.01.2025
Kolorektales Karzinom
Nachrichten

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

16.01.2025
Primäre Glomerulonephritiden
Nachrichten

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten